Global Radiopharmaceuticals and Theranostics Market — Intelligence Report

The global radiopharmaceuticals and theranostics market is entering a structural growth phase as oncology care shifts toward targeted diagnostics, precision staging, and receptor-directed treatment. Nexvora Intelligence estimates the market at approximately $•••–••• billion in 2025, with expansion supported by rising PET imaging volumes, broader adoption of theranostic workflows, and rapid investment in radioligand therapy platforms. The market remains anchored in diagnostic radiopharmaceuticals, but therapeutic radiopharmaceuticals are becoming the primary value-creation engine.

Theranostics is reshaping the commercial logic of nuclear medicine by linking patient selection, imaging confirmation, dosimetry, and treatment into a single clinical pathway. Prostate cancer remains the most mature use case, particularly through PSMA-targeted approaches, while neuroendocrine tumors continue to provide an established proof point for receptor-based radiopharmaceutical treatment. Pipeline activity is expanding into breast cancer, lung cancer, pancreatic cancer, renal cancers, and hematologic malignancies, although clinical translation will depend on target specificity, safety profile, isotope availability, and reimbursement clarity.

Market growth is constrained less by clinical demand than by infrastructure and execution capacity. Radiopharmaceutical manufacturing requires specialized isotope sourcing, radiochemistry capabilities, short-cycle logistics, regulatory-grade quality systems, and proximity to treatment centers. As therapeutic isotopes scale, supply-chain resilience is becoming a strategic differentiator, particularly for players with secured isotope access, distributed manufacturing networks, and integrated cold-chain or time-sensitive delivery capabilities.

North America is expected to remain the leading regional market through the forecast period, supported by high PET utilization, specialist oncology centers, reimbursement depth, and active commercial rollout of radioligand therapies. Europe maintains strong scientific and clinical leadership, particularly in nuclear medicine practice, but market access remains more fragmented. Asia-Pacific represents the fastest-expanding growth pool, driven by hospital infrastructure investment, rising cancer incidence, and increasing deployment of PET/CT and cyclotron capacity in major healthcare markets.

Nexvora Intelligence developed this market opening using proprietary bottom-up and top-down modeling across diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, and theranostic clinical pathways.

The analysis incorporates modeled procedure volumes, treatment adoption curves, regional infrastructure maturity, pricing bands, isotope supply constraints, and expected clinical pipeline conversion scenarios.

All market figures in this report opening are Nexvora modeled estimates and should be interpreted as analytical ranges rather than externally sourced statistics.

Forecast assumptions are scenario-tested against reimbursement conditions, manufacturing scalability, hospital nuclear medicine capacity, and competitive commercialization dynamics across major regions.